Search bioRxiv⌕ Search

Biology subjects

Borchmann, S.

Publications and source records attributed to Borchmann, S..

3 recordsLinked to original sources

pyfraglib: An integrated cfDNA fragmentomics platform

SummaryCell-free DNA (cfDNA) fragmentomics is the analysis of a diverse set of cfDNA fragment features, e.g. fragment length profiles, windowed protection scores, and end motifs. As such it requires software tooling for fragment extraction, statistical feature modeling, and cohort-level comparative analysis. In silico simulations can facilitate the development and validation of new methods by generating testing datasets with known ground truth. Existing tools address individual aspects of this workflow but none provide all necessary capabilities within a single package. ResultsWe present pyfraglib, a platform integrating fragment extraction from short- and long-read sequencing, statistical feature modeling (Gaussian mixture and NMF decomposition of fragment length profiles, end motif diversity, windowed protection scores), cohort-level differential testing of said features, and a simulation module. The library is exposed through a command-line interface, a Python API, and a Nextflow pipeline. We demonstrate pyfraglib in two ways. First, on two simulated 20-sample cohorts we show that pyfraglibs per-sample and cohort-level analyses recover the differences introduced by construction. Second, we apply pyfraglib to 88 cfDNA samples from a central nervous system lymphoma (CNSL) study and construct a fragmentomics score combining an NMF signature with end motif and WPS summaries via a classifier trained on cerebrospinal fluid and healthy donor plasma samples. As a proof of concept and applied to 66 baseline patient plasma samples, the score identifies a high-risk subgroup with worse failure-free survival (log-rank p=0.0247). Conclusionspyfraglib integrates sample- and cohort-level fragmentomics analyses as well as in silico simulation within a consistently engineered Python framework. pyfraglib source code and documentation are available at https://github.com/schwarzlab-ccb/pyfraglib.

bioinformatics↗

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells:Potency despite risk of translocations

BackgroundChimeric antigen receptor (CAR)-T cells are therapeutic breakthroughs against advanced non-Hodgkin lymphomas and myelomas. On the other hand, no CAR-T cell product has been so far clinically approved for therapy of Hodgkin Lymphoma (HL), T cell lymphoma (TCL), or Epstein-Barr-Virus (EBV)-associated lymphoproliferative diseases (EBV-LPDs). CD30 (TNFRSF8) is commonly expressed on HL and on subsets of TCL and EBV-LPDs. CD30CAR-T cells generated via transduction with viral vectors have been tested in clinical trials, showing overall good responses against HL. CAR-T cells produced entirely with locus-specific gene editing methods are emerging as attractive next-generation engineered cell products for ease of multiple seamless cell modifications. MethodsUsing CRISPR/Cas9-mediated techniques, we optimized homology-directed repair templates (HDRTs) and performed all-in-one multiplex editing to knock-in (KI) CD30CAR within the TCR constant (TRAC) locus and to simultaneously knock-out (KO) PD-1 or/and {beta}2M. CD30CAR-T cells were tested in CD30+ cell models of HL, TCL, and EBV-LPDs. ResultsWe compared mouse versus human anti-CD30 scFv designs in HDRTs incorporating TRAC homology arms, FcIg spacer/detection domain, and CD28 / CD3{zeta} signaling domains. We obtained an average of 30% TRACKICD30CAR-T cells and efficient in vitro cytotoxicity with CD30+ cell targets. CARs incorporating the high-affinity humanized 5F11 scFv showed the highest CAR expression, and the editing templates were further modified to incorporate a truncated CD34 (tCD34) spacer/detection domain. 5F11-CD30CAR-tCD34-T cells showed high CAR-KI rates (approx. 50-80% 12-14 days after editing) and potency in vitro and in vivo. Subsequently, we tested all-in-one CAR KI with additional KOs by co-electroporation of guide RNAs (gRNAs) targeting the genes encoding PD-1 or /and {beta}2M to improve function and allow for improved cell persistence in allogeneic recipients, respectively. Compared with CD30CAR-T cells, CD30CAR-{beta}2MKO-T cells were similarly viable and functional and showed low risk of translocations. PD1KO enabled CD30CAR-T cells to produce higher levels of cytotoxic features upon exposure to targets. However, simultaneous {beta}2MKO and PD-1KO compromised the expansion capacity of CD30CAR-T cells and resulted in detectable translocations. ConclusionsNon-virally engineered 5F11-CD30CAR-T cells represent a novel cell therapy modality against CD30+ lymphomas. Multiplex editing remains to be optimized to avoid unwanted genomic alterations and chromosomal translocations.

cancer biology↗

An atlas of bacterial and viral associations in cancer

Host tissue infections by bacteria and viruses can cause cancer. Massively parallel sequencing now routinely generates datasets large enough to contain detectable traces of bacterial and viral nucleic acids of taxa that colonize the examined tissue or are integrated into the host genome. However, this hidden resource has not been comprehensively studied in large patient cohorts. In the present study, 3000 whole genome sequencing datasets are leveraged to gain insight into novel links between viruses, bacteria and cancer. The resulting map confirms known links and expands current knowledge by identifying novel associations. Moreover, the detection of certain bacteria or viruses is associated with profound differences in patient and tumor phenotypes, such as patient age, tumor stage, survival, somatic mutations in cancer genes or gene expression profiles. Overall, these results provide a detailed, unprecedented map of links between viruses, bacteria and cancer that can serve as a reference for future studies.

genomics↗